Elements to Consider for a Comprehensive Assessment of the Public Health IMPACT of Vaccination
Author(s)
van Oorschot D1, Lee C2, Meszaros K3, Shantakumar S2, Beck E4
1GSK Vaccines, Wavre, WBR, Belgium, 2GSK, Singapore, Singapore, 3GSK, Wavre, Belgium, 4Vaccines Europe Market Access Working Group, Brussels, BY, Belgium
OBJECTIVES Vaccines differ from therapeutic drugs as they provide broad and distinctive benefits associated with prevention at the population level, beyond the individual. Public health impact (PHI) of vaccination is a key measure of these benefits. However, analysis and consideration of the PHI in vaccine policy decision-making can differ significantly across assessing bodies. This review provides an overview of different elements that contribute to the extensive PHI considered for three vaccine examples implemented in national immunization programs. METHODS A scoping review of three pediatric, adolescent and adult vaccines (meningococcal serogroup B, human papillomavirus and herpes zoster) was conducted to assess whether and which elements of the PHI have been explored and considered by National Immunisation Task Advisory Groups and Health Technology Assessment Bodies. Their meeting minutes and public summary documents were reviewed, as well as relevant published evidence with focus on the PHI analysis for vaccination. RESULTS Six categories, each spanning distinctive elements considered in the PHI analysis were identified: (1)morbidity, mortality, and disability; (2)herd-immunity and disease control; (3)summary measures of the quality of life capturing impact of the disease on the patient, surrounding families and wider networks; (4)costs related to morbidity/mortality/disability for the patient, households, healthcare-system and society; (5)social severity preferences; and (6)considerations of discounting. CONCLUSIONS Elements considered in the PHI analysis are broad, ranging from morbidity to social severity preferences as well as discounting of costs and health benefits. This range, including the significant impact of vaccination beyond the vaccinated, shows the need for a different value assessment framework for vaccines than that for therapeutic drugs. By capturing the comprehensive and distinctive benefits associated with vaccination, the extensive PHI analysis allows decision makers to infer about vaccine impact in a real-world setting on their population of interest. It provides relevant insights, which will help them in optimizing vaccination schedules in their jurisdictions.
Conference/Value in Health Info
2020-09, ISPOR Asia Pacific 2020, Seoul, South Korea
Value in Health Regional, Volume 22S (September 2020)
Code
PIN30
Topic
Epidemiology & Public Health, Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Public Health, Public Spending & National Health Expenditures, Reimbursement & Access Policy, Value Frameworks & Dossier Format
Disease
Multiple Diseases, Vaccines